Viread Science Korea release positive clinical results on Viread

Published: 2013-06-17 06:58:00

Updated: 2013-06-17 06:58:00

Viread Science Korea Thursday announced new data from follow-up studies in China, Korea and Europe, which compared Viread (tenofovir disoproxil fumarate) to Hepsera (adefovir dipivoxil) over 48 weeks of treatment among primarily treatment-naive patients with chronic hepatitis B virus (HBV) infect...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK